brain-gut-microbiota interactions and intestinal...

45
Wendy A. Henderson, PhD, CRNP, FAAN Chief, Digestive Disorders Unit Division of Intramural Research Brain-Gut-Microbiota Interactions and Intestinal Health

Upload: vanminh

Post on 11-Apr-2018

253 views

Category:

Documents


3 download

TRANSCRIPT

  • Wendy A. Henderson, PhD, CRNP, FAANChief, Digestive Disorders UnitDivision of Intramural Research

    Brain-Gut-Microbiota Interactions and Intestinal Health

  • Wendy A. Henderson, PhD, MSN, CRNP

    Early Life Brain-Gut Microbiota Signaling

    Cong, Henderson, et al., Advances in Neonatal Care, 2015

  • Wendy A. Henderson, PhD, MSN, CRNP

    Nutri-epigenetics

    Joseph, Abey, Henderson, ONF, 2016

  • Wendy A. Henderson, PhD, MSN, CRNP

    Key Facts About Stress Effects on Intestinal Health

    Up to 20% of the US population report stress induced gastrointestinal (GI) symptoms

    Single most common reason for emergency visits Top 10 reasons for outpatient visits 30 billion in costs annually Evidence that chronic stress affects intestinal

    health across the lifespan

  • Wendy A. Henderson, PhD, CRNP, FAAN

    Biobehavioral Branch: Dr. Wendy Henderson

    Targeted Treatments

    Stress-InducedGastrointestinal

    Symptoms

    Phenotypic Characterization

    Personalized Profile

    Implementation Science

  • Wendy A. Henderson, PhD, MSN, CRNP

    Innovation-Gastrointestinal Pain Pointer

    Developed by Henderson & Zuccolotto, PHS Invention #E-175-2010

    Henderson et al., Gastroenterology Nursing, 2017

  • Brain-Gut Natural History Study

    Hypothesis:

    Design:

    Male/Female Age 13-45 years No known organic cause

    NIH Clinical Trial #NCT00824941

    STRESS

    Intestinal Permeability

    Microbial Translocation

    Abdominal Pain

    Control IBS

    OverweightControl

    IBS + Overweight

    - +

    +

    -

  • Wendy A. Henderson, PhD, CRNP, FAAN

    VariableOveralln = 90

    Controln = 62

    IBSn = 28

    IBS-Dn = 13

    IBS-Cn = 12

    Gender n (%)

    Male 45 (50%) 33 (53.2%) 12 (42.9%) 5 (38.5%) 5 (41.7%)

    Female 45 (50%) 29 (46.8%) 16 (57.1%) 8 (61.5%) 7 (58.3%)

    Race n (%)

    White 45 (50%) 30 (48.4%) 15 (53.6%) 8 (61.5%) 6 (50%)

    Black 26 (28.9%) 17 (27.4%) 9 (32.1%) 2 (15.4%) 6 (50%)

    Asian 13 (14.4%) 10 (16.1%) 3 (5.2%) 2 (15.4%) 0

    Other 6 (6.7%) 5 (8.1%) 1 (3.6%) 1 (7.7%) 0

    Age (yrs) 27.82 7.85 28.22 8.05 26.93 7.45 26.62 6.99 27.50 8.09

    Participant CharacteristicsProtocol 09-NR-0064, PI Henderson

  • Wendy A. Henderson, PhD, CRNP, FAAN

    Non-invasive Method to Assess Intestinal Permeability

    Del Valle Pinero, et al., Henderson, Clinica Chimica Acta, 2013

  • Wendy A. Henderson, PhD, CRNP, FAAN

    Novel LC-MS Method to Intestinal Permeability

    Del Valle Pinero et al., Henderson, Clinica Chimica Acta, 2013

  • Wendy A. Henderson, PhD, CRNP, FAAN

    Induce Stress Experimentally

    Del Valle Pinero, et al., Henderson, Clinica Chimica Acta, 2013

    Protocol 09-NR-0064, PI HendersonN=126 enrolled

  • Wendy A. Henderson, PhD, MSN, CRNP

    Human Response to Sugar Challenge and the Microbiome

  • Wendy A. Henderson, PhD, MSN, CRNP

    Microbial taxa associated with Visceral Pain

  • Brain-Gut Natural History Study

    NIH Clinical Trial #NCT00824941

    STRESS

    Intestinal Permeability

    Microbial Translocation

    Abdominal Pain

  • Model of Microbial Translocation

  • Model of Microbial Translocation

    IFABP: p = NS

  • Model of Microbial Translocation

    IFABP: p = NS

    LBP: p = 0.014

  • Model of Microbial Translocation

    IFABP: p = NS

    sCD14: p = 0.067

    LBP: p = 0.014

  • Pathway Analysis of Significant Genes

    Abey, et al., Henderson, BBA Clinical, 2016

  • Electron Microscopy of Gold-labeled Plasma EVs

    CD9 Lysozyme

    IGg2aIGg1 MUC1 MUC2

    +MT Control +MT Control

    Abey, et al., Henderson, BBA Clinical, 2016

  • Time = 0 h Time = 8 h

    [-Lyz]

    [+Lyz]

    Top Canonical Pathways from Affymetrix

    Pyridoxal 5-phosphate Salvage PathwaySalvage Pathways of Pyrimidine RibonucleotidesAtherosclerosis Signaling

    Top Molecular and Cellular Functions from Affymetrix

    Cell-To-Cell Signaling and Interaction Cellular Movement Cellular Assembly and Organization

    Abey, et al., Henderson, BBA Clinical, 2016

  • 0

    0.5

    1

    1.5

    2

    CD9 NT5E PD-L1 IL7R CD68

    Fold

    RN

    A or

    Pro

    tein

    (-Ly

    z / +

    Lyz)

    RNA [-Lyz]

    RNA [+Lyz]

    Protein [-Lyz]

    Protein [+Lyz]

    Significant RNA and Protein with Lysozyme

    Nanostring analysis of epithelial cells which survived this injury for 8 h [+ vs -Lyz] shows five RNA/Proteins which are part of LYZ-specific molecular cell response to injury or stress:

    Abey, et al., Henderson, BBA Clinical, 2016

  • Lysozyme: innate immunity and antimicrobial

    Lysozyme

    Abey, et al., Henderson, BBA Clinical, 2016

  • Wendy A. Henderson, PhD, MSN, CRNP

    Mucosa Adherent Microbiome

    Fourie, et al., Henderson, Gut Microbes, 2016

  • Wendy A. Henderson, PhD, MSN, CRNP

    Chronic Stress Murine Model

    Fourie, et al., Henderson, Gut Microbes, 2017

  • Wendy A. Henderson, PhD, MSN, CRNP

    Chronic Stress and Murine Microbiota

    Circular cladogram (LEfSe analysis) showing taxa that are more abundantly expressed in water avoidance (WA) stressed animals (i.e. animals which exhibit persistent stress induced gastrointestinal symptoms) in green and taxa more abundantly expressed in control (C) animals in red. Enrichment of the phyla Proteobacteria (n) and Actinobacteria (c) are characteristic of WA animals.

    Fourie, et al., Henderson, Gut Microbes, 2017

  • Wendy A. Henderson, PhD, MSN, CRNPFourie et al., Henderson. Gastroenterology, 2015, 148(4):S-777.

    Host-Microbiome Interaction

  • Effects on Epithelial Cell Barrier Function

    Barrier function measured in response to Dexamethasone and Butyrate exposure:

    Butyrate

    Cell-cell junctions mediate gut epithelial permeability

    TEER measures epithelial permeability

    Robinson, Abey, et al., Henderson, under review.

  • ZO-1 Occludin Merge

    Untreated

    +DEX

    Occludin: trans-membrane protein which facilitates barrierfunction of the epithelial tight junction.

    ZO-1: scaffolding protein physically linking the actincytoskeleton to Occludin and other trans-membrane tightjunction proteins.

    +DEX+Butyrate

    Disruption of Tight Junctions by Dexamethasone and Butyrate

    Robinson, Abey, et al., Henderson, under review.

  • Untreated ChronicDexamethasone

  • Targeted Treatments

    Grenham et al., Frontiers in Physiology, 2011

  • Wendy A. Henderson, PhD, MSN, CRNP

    Ongoing and Future Studies

    Targeting GI Epithelial Integrity to Improve Arterial Inflammation in HIV

    Collaboration with Dr. Janet Lo Assistant Professor of MedicineMassachusetts General HospitalHarvard Medical SchoolFunding: NIH 1R01HL123351

  • Study Aims

    Aim 1: Cross-sectional study to investigate the relationship between:

    Aim 2: RCT to investigate the effects of a GLP-2 analogue (teduglutide) on:

    GI epithelial integrity Intestinal permeability Markers of microbial translocation, Markers of immune activation Evidence of coronary atherosclerosis/arterial

    inflammation

  • Hypothesis

    We hypothesize that increased microbial translocation resulting from impaired epithelial integrity and impaired mucosal immunitytriggers the innate immune system, causing proatherogenic monocyteand macrophage activation and atherosclerotic disease development in HIV disease.

    GI Epithelial Integrity

    Microbial Translocation

    Immune Activation

    Atherosclerosis and Arterial Inflammation

  • Study Procedures

    Gut epithelial integrity/barrier function Colonoscopy/Endoscopy

    Tissue biopsyGI epithelial tight junctionsGI epithelial apoptosisCharacterize tissue T-cells and

    macrophages Blood: Microbial translocation Intestinal permeability Microbiome

  • VISIT 3:Colonoscopy

    EGD

    VISIT 4:FDG-PET

    VISIT 2:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 1:(Screen Visit)Cardiac CTA*

    VISIT 9:Colonoscopy

    EGD

    VISIT 10:FDG-PET

    VISIT 8:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 7:Cardiac CTA

    BASELINE VISITS INTERVENTION END OF STUDY VISITS

    STUDY DESIGN

    60 HIV+ Subjects

    10 Healthy Controls

    10 HIV+ Subjects (Visits 1-2)

    10 Healthy Controls (Visits 1-2)

    Cross Sectional Study:

    20 Healthy Controls 70 HIV+ Subjects

    Flow of participants

    *Only for participants who do Visits 1-4

    VISIT 5 & 6(Safety Visits)

    Daily SQ injection of teduglutide or

    placebo for 6 months

    Aim 1: 7 HIV patients and 9 Healthy Controls

  • VISIT 3:Colonoscopy

    EGD

    VISIT 4:FDG-PET

    VISIT 5 & 6(Safety Visits)

    Daily SQ injection of teduglutide or

    placebo for 6 months

    VISIT 2:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 1:(Screen Visit)Cardiac CTA*

    VISIT 9:Colonoscopy

    EGD

    VISIT 10:FDG-PET

    VISIT 8:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 7:Cardiac CTA

    BASELINE VISITS INTERVENTION END OF STUDY VISITS

    STUDY DESIGNFlow of participants

    60 HIV+ Subjects

    10 Healthy Controls

    10 HIV+ Subjects (Visits 1-2)

    10 Healthy Controls (Visits 1-2) Interventional Study:

    60 HIV+ Subjects

    Randomization

    Aim 2: 6 HIV patients enrolledAim 1: 7 HIV patients and 9 Healthy Controls

  • VISIT 3:Colonoscopy

    EGD

    VISIT 4:FDG-PET

    VISIT 2:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 1:(Screen Visit)Cardiac CTA*

    VISIT 9:Colonoscopy

    EGD

    VISIT 10:FDG-PET

    VISIT 8:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 7:Cardiac CTA

    BASELINE VISITS INTERVENTION END OF STUDY VISITS

    STUDY DESIGNFlow of participants

    60 HIV+ Subjects

    10 Healthy Controls

    10 HIV+ Subjects (Visits 1-2)

    10 Healthy Controls (Visits 1-2) Interventional Study:

    60 HIV+ Subjects

    VISIT 5 & 6(Safety Visits)

    Daily SQ injection of teduglutide or

    placebo for 6 months

    Aim 2: 6 HIV patients enrolledAim 1: 7 HIV patients and 9 Healthy Controls

  • VISIT 3:Colonoscopy

    EGD

    VISIT 4:FDG-PET

    VISIT 2:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 1:(Screen Visit)Cardiac CTA

    VISIT 9:Colonoscopy

    EGD

    VISIT 10:FDG-PET

    VISIT 8:Intestinal

    PermeabilityDEXA

    HR-pQCT

    VISIT 7:Cardiac CTA

    BASELINE VISITS INTERVENTION END OF STUDY VISITS

    STUDY DESIGNFlow of participants

    60 HIV+ Subjects

    10 Healthy Controls

    10 HIV+ Subjects (Visits 1-2)

    10 Healthy Controls (Visits 1-2) Interventional Study:

    60 HIV+ Subjects

    VISIT 5 & 6(Safety Visits)

    Daily SQ injection of teduglutide or

    placebo for 6 months

    Aim 2: 6 HIV patients enrolledAim 1: 7 HIV patients and 9 Healthy Controls

  • Microbial AssaysSchematic depicting lateral flow assay in one arm

    Proposed schematic for multiplexed detection of diarrhea-causing pathogens

    Nonprovisional Worldwide PCT Patent Application No.: PCT/US16/32788Kim, Henderson, Abey, Fourie, & Ferguson, 2015

  • Microbial AssaysSchematic depicting lateral flow assay in one arm

    Proposed schematic for multiplexed detection of diarrhea-causing pathogens

    Worldwide PCT Patent Application No.: PCT/US16/32788Kim, Henderson, Abey, Fourie, & Ferguson, 2016

  • Wendy A. Henderson, PhD, CRNP, FAAN

    Biobehavioral Branch: Dr. Wendy Henderson

    Clinical Applications

    Stress-Induced Gastrointestinal

    Symptoms

    Gastrointestinal Pain Pointer

    Personalized Profile

    Implementation Science

  • AcknowledgmentsLab Members:Ana Diallo, PhD, MPH, BSN, Postdoctoral IRTAJeffrey Robinson, PhD, Postdoctoral IRTAChristina Boulineaux, MS, Postbac IRTAStephanie Prescott, MSN, CRNP, GPP student

    Prior Lab Members:Paule Joseph, PhD, MSN, CRNP, Postdoctoral IRTA, OWD FundedKristen Weaver, PhD, BS, BSN, MSN, CRNP, GPP StudentNatneal Kenea, BS, Special VolunteerOnyi Ozyochi, BS, Special Volunteer, OTIE fundedLeeAnne Sherwin, PhD, MS, CRNP, Special VolunteerFaye Harrell, MSN, CRNP, Special VolunteerNicolaas Fourie, PhD, Special VolunteerSarah Abey, PhD, BSN, Prior- Nurse Specialist, Research

    Collaborators:Kong Chen, PhD (NIDDK)Colleen Hadigan, MD (NIAID)David Kleiner, MD, PhD (NCI)Alan Remaley, MD, PhD (NHLBI, DLM)Lorenzo Leggio, MD, PhD (NIAAA & NIDA)Peter Walter, PhD, (NIDDK)

    NINRDivision of Intramural ResearchDan Wang, PhDAnn Cashion, PhD, RN, FAANSue Wingate, PhD, CRNPBrian Walitt, MD, MPH

    Extramural Collaborators:Margaret Heitkemper, PhD, RN, U of Washington Anthony Zuccolato, PST, Inc.Chang Hee Kim, PhD, GoDxJohn Wiley, U of MichiganGreg Goyne, Nanostring Tech. Rob Shulman, BaylorSecondGenomeNCI- Fredrick

    ParticipantsCNS IRBMetabolic UnitCC Nurses & Staff

    Office of Workforce DiversityOffice of Intramural Training and EducationCommunity College Summer Enrichment ProgramAmgen

  • Wendy A. Henderson, PhD, CRNP, FAANChief, Digestive Disorders UnitDivision of Intramural Research

    Brain-Gut-Microbiota Interactions and Intestinal Health

  • ChronicDEX and Butyrate

    Slide Number 1Early Life Brain-Gut Microbiota SignalingNutri-epigeneticsKey Facts About Stress Effects on Intestinal HealthSlide Number 5Innovation-Gastrointestinal Pain PointerBrain-Gut Natural History StudySlide Number 8Slide Number 9Slide Number 10Slide Number 11Human Response to Sugar Challenge and the MicrobiomeMicrobial taxa associated with Visceral PainBrain-Gut Natural History StudyModel of Microbial TranslocationModel of Microbial TranslocationModel of Microbial TranslocationModel of Microbial TranslocationPathway Analysis of Significant GenesElectron Microscopy of Gold-labeled Plasma EVsSlide Number 21Significant RNA and Protein with LysozymeLysozyme: innate immunity and antimicrobial Mucosa Adherent MicrobiomeChronic Stress Murine ModelChronic Stress and Murine MicrobiotaHost-Microbiome InteractionEffects on Epithelial Cell Barrier FunctionDisruption of Tight Junctions by Dexamethasone and ButyrateSlide Number 30Targeted TreatmentsOngoing and Future StudiesStudy AimsHypothesisStudy ProceduresSTUDY DESIGNSTUDY DESIGNSTUDY DESIGNSTUDY DESIGNMicrobial AssaysMicrobial AssaysSlide Number 42AcknowledgmentsSlide Number 44Slide Number 45